WallStreetZenWallStreetZen

NASDAQ: BDTX
Black Diamond Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for BDTX

Based on 2 analysts offering 12 month price targets for Black Diamond Therapeutics Inc.
Min Forecast
$11.00+109.92%
Avg Forecast
$13.50+157.63%
Max Forecast
$16.00+205.34%

Should I buy or sell BDTX stock?

Based on 2 analysts offering ratings for Black Diamond Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BDTX stock forecasts and price targets.

BDTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-16
lockedlocked$00.00+00.00%2024-04-08

1 of 1

Forecast return on equity

Is BDTX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.34%

Forecast return on assets

Is BDTX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BDTX revenue forecast

What is BDTX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$2.6M
Avg 2 year Forecast
$19.5M
Avg 3 year Forecast
$36.5M

BDTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BDTX$5.24$13.50+157.63%Buy
ATNM$9.85$28.40+188.32%Strong Buy
INZY$4.73$17.00+259.41%Strong Buy
IVVD$2.45$9.50+287.76%Strong Buy
XOMA$25.66$57.00+122.14%Buy

Black Diamond Therapeutics Stock Forecast FAQ

Is Black Diamond Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BDTX) stock is to Buy BDTX stock.

Out of 2 analysts, 0 (0%) are recommending BDTX as a Strong Buy, 2 (100%) are recommending BDTX as a Buy, 0 (0%) are recommending BDTX as a Hold, 0 (0%) are recommending BDTX as a Sell, and 0 (0%) are recommending BDTX as a Strong Sell.

If you're new to stock investing, here's how to buy Black Diamond Therapeutics stock.

What is BDTX's revenue growth forecast for 2025-2027?

(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.99%.

Black Diamond Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BDTX's revenue for 2025 to be $147,944,848, with the lowest BDTX revenue forecast at $147,944,848, and the highest BDTX revenue forecast at $147,944,848. On average, 1 Wall Street analysts forecast BDTX's revenue for 2026 to be $1,095,241,899, with the lowest BDTX revenue forecast at $1,095,241,899, and the highest BDTX revenue forecast at $1,095,241,899.

In 2027, BDTX is forecast to generate $2,054,127,026 in revenue, with the lowest revenue forecast at $731,286,322 and the highest revenue forecast at $3,931,507,773.

What is BDTX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BDTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is BDTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BDTX price target, the average BDTX price target is $13.50, with the highest BDTX stock price forecast at $16.00 and the lowest BDTX stock price forecast at $11.00.

On average, Wall Street analysts predict that Black Diamond Therapeutics's share price could reach $13.50 by May 16, 2025. The average Black Diamond Therapeutics stock price prediction forecasts a potential upside of 157.63% from the current BDTX share price of $5.24.

What is BDTX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BDTX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.